# SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES

> **NIH NIH R01** · DUKE UNIVERSITY · 1987 · $150,889

## Abstract

One of the most promising clinical applications for monoclonal antibodies
is in the selective and complete removal of malignant cells from human bone
marrow prior to autologous transplantation.  To measure elimination of
tumor cells a clonogenic assay has been developed that utilizes Burkitt's
lymphoma tumor cell lines which bear one or more of a group of markers
including the common acute lymphoblastic leukemia antigen (CALLA), gp 26,
Bl, Ia, HLA, B2 microglobulin and certain T cell differentiation antigens.
One or more monoclonal antibodies are available which react with each of
these markers.  Using this model, requirements for the elimination of
malignant cells from human bone marrow can be explored systematically.  We
will determine whether susceptibility of different tumor cell lines can be
correlated with antigen binding, antigenic modulation, complement
activation, complement binding, osmotic fragility or membrane repair.
Resistant clones can be isolated, permitting analysis of mechanisms by
which tumor cells avoid antibody mediated cytotoxicity.  Understanding
mechanisms of resistance may permit a more rational approach to the
elimination of malignant cells from human bone marrow.  Treatment of bone
marrow with antibodies against differentiation antigens such as CALLA or gp
26 removes subpopulations of normal cells as well as tumor cells.
Techniques have been developed for the isolation of CALLA+ and gp26+
precursors from fetal liver and bone marrow.  Monoclonal reagents will be
used as probes to define the role of these differentiation antigens in
normal lymphoid development and function.

## Key facts

- **NIH application ID:** 3179309
- **Project number:** 5R01CA039930-04
- **Recipient organization:** DUKE UNIVERSITY
- **SAM.gov UEI:** TP7EK8DZV6N5
- **Principal Investigator:** OLIVER MICHAEL COLVIN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $150,889
- **Award type:** 5
- **Project period:** 1984-10-01 → 1988-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3179309

## Citation

> US National Institutes of Health, RePORTER application 3179309, SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES (5R01CA039930-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3179309. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*